Home Healthcare Biotechnology Gene Vector Market

Gene Vector Market Size, Share & Trends Analysis Report By Type (Viral Vectors, Non-Viral Vectors), By Application (Gene Therapy, Vaccinology, Others), By Diseases (Oncology, Genetic Disorders, Infectious Diseases, Others), By End Use (Pharmaceutical and Biotechnology Companies, Academic & Research Institutes, CROs, CDMOs) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: November 26, 2025 | Author: Debashree B | Format: | Report Code: SR7433DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Gene Vector Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Viral Vectors
      1. Adenoviral vectors
      2. Adeno associated viral vectors
      3. Retroviral vectors
      4. Lentiviral vectors
      5. Herpes Simplex Virus (HSV) Vectors
      6. Others
    2. Non-Viral Vectors
      1. Plasmid DNA
      2. Lipid Nanoparticles
      3. Polymer-based Vectors
      4. Others
  2. Gene Vector Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Gene Therapy
    2. Vaccinology
    3. Others
  3. Gene Vector Market, By Diseases 2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Genetic Disorders
    3. Infectious Diseases
    4. Others
  4. Gene Vector Market, By End Use 2022-2034 (USD MILLION/ Units)
    1. Pharmaceutical and Biotechnology Companies
    2. Academic & Research Institutes
    3. CROs
    4. CDMOs
  5. Regional Gene Vector Market
    1. North America
      1. North America Gene Vector Market By Type 2022-2034 (USD MILLION/ Units)
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
      2. North America Gene Vector Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gene Therapy
        2. Vaccinology
        3. Others
      3. North America Gene Vector Market By Diseases 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Genetic Disorders
        3. Infectious Diseases
        4. Others
      4. North America Gene Vector Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biotechnology Companies
        2. Academic & Research Institutes
        3. CROs
        4. CDMOs
      5. U.S.
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      6. Canada
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
    2. Europe
      1. Europe Gene Vector Market By Type 2022-2034 (USD MILLION/ Units)
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
      2. Europe Gene Vector Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gene Therapy
        2. Vaccinology
        3. Others
      3. Europe Gene Vector Market By Diseases 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Genetic Disorders
        3. Infectious Diseases
        4. Others
      4. Europe Gene Vector Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biotechnology Companies
        2. Academic & Research Institutes
        3. CROs
        4. CDMOs
      5. U.K.
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      6. Germany
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      7. France
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      8. Spain
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      9. Italy
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      10. Russia
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      11. Nordic
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      12. Benelux
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      13. Rest of Europe
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
    3. APAC
      1. APAC Gene Vector Market By Type 2022-2034 (USD MILLION/ Units)
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
      2. APAC Gene Vector Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gene Therapy
        2. Vaccinology
        3. Others
      3. APAC Gene Vector Market By Diseases 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Genetic Disorders
        3. Infectious Diseases
        4. Others
      4. APAC Gene Vector Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biotechnology Companies
        2. Academic & Research Institutes
        3. CROs
        4. CDMOs
      5. China
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      6. Korea
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      7. Japan
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      8. India
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      9. Australia
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      10. Taiwan
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      11. South East Asia
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      12. Rest of Asia-Pacific
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
    4. Middle East and Africa
      1. Middle East and Africa Gene Vector Market By Type 2022-2034 (USD MILLION/ Units)
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
      2. Middle East and Africa Gene Vector Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gene Therapy
        2. Vaccinology
        3. Others
      3. Middle East and Africa Gene Vector Market By Diseases 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Genetic Disorders
        3. Infectious Diseases
        4. Others
      4. Middle East and Africa Gene Vector Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biotechnology Companies
        2. Academic & Research Institutes
        3. CROs
        4. CDMOs
      5. UAE
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      6. Turkey
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      7. Saudi Arabia
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      8. South Africa
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      9. Egypt
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      10. Nigeria
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      11. Rest of MEA
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
    5. LATAM
      1. LATAM Gene Vector Market By Type 2022-2034 (USD MILLION/ Units)
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
      2. LATAM Gene Vector Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gene Therapy
        2. Vaccinology
        3. Others
      3. LATAM Gene Vector Market By Diseases 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Genetic Disorders
        3. Infectious Diseases
        4. Others
      4. LATAM Gene Vector Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biotechnology Companies
        2. Academic & Research Institutes
        3. CROs
        4. CDMOs
      5. Brazil
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      6. Mexico
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      7. Argentina
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      8. Chile
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      9. Colombia
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
      10. Rest of LATAM
        1. Viral Vectors
          1. Adenoviral vectors
          2. Adeno associated viral vectors
          3. Retroviral vectors
          4. Lentiviral vectors
          5. Herpes Simplex Virus (HSV) Vectors
          6. Others
        2. Non-Viral Vectors
          1. Plasmid DNA
          2. Lipid Nanoparticles
          3. Polymer-based Vectors
          4. Others
        3. Gene Therapy
        4. Vaccinology
        5. Others
        6. Oncology
        7. Genetic Disorders
        8. Infectious Diseases
        9. Others
        10. Pharmaceutical and Biotechnology Companies
        11. Academic & Research Institutes
        12. CROs
        13. CDMOs
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.